Risk factors and mortality associated with resistance to first-line antiretroviral therapy: Multicentric cross-sectional and longitudinal analyses

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 5, 2015, Pages 527-535

  Pinoges, Loretxu ^a   Schramm, Birgit ^a   Poulet, Elisabeth ^a   Balkan, Suna ^b   Szumilin, Elisabeth ^b   Ferreyra, Cecilia ^b   Pujades Rodríguez, Mar ^a,c  

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

HIV infection; longitudinal studies; mortality; outcome evaluation; resistance

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; VIRUS RNA;

ADULT; AGE; ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; CAMBODIA; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAWI; MALE; MEDICATION COMPLIANCE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; UGANDA; VIRUS LOAD; AFRICA; CLINICAL TRIAL; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MULTICENTER STUDY; PROCEDURES; SURVIVAL; VIROLOGY;

ADULT; AFRICA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAMBODIA; CROSS-SECTIONAL STUDIES; DRUG MONITORING; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; RISK FACTORS; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 84925232876     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000513     Document Type: Article

References (51)

1. WHO, UNICEF, UNAIDS. Global Update on HIV Treatment 2013: Results, Impact and Opportunities. Geneva, Switzerland: WHO Document Production Services; 2013.
2. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 2013;10:e1001418.
3. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155:209-216.
4. Bertagnolio S, De LA, Vitoria M, et al. Determinants of HIV drug resistance and public health implications in low-and middle-income countries. Antivir Ther. 2012;17:941-953.
5. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther. 2013;18: 115-123.
6. Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(suppl 2):1-13.
7. Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis. 2012;54(suppl 4):S245-S249.
8. Ahoua L, Guenther G, Pinoges L, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIVpositive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9:81.
9. Ahoua L, Guenther G, Rouzioux C, et al. Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1-and 2-year outcomes in rural Uganda. BMC Pediatr. 2011;11:67.
10. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
11. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007;21: 2293-2301.
12. Ferreyra C, Yun O, Eisenberg N, et al. Evaluation of clinical and immunological markers for predicting virological failure in a HIV/AIDS treatment cohort in Busia, Kenya. PLoS One. 2012;7:e49834.
13. Pujades-Rodriguez M, Schramm B, Som L, et al. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Trop Med Int Health. 2011 Feb;16 (2):205-13 2010.
14. Arnedo M, Alonso E, Eisenberg N, et al. Monitoring HIV viral load in resource limited settings: still a matter of debate? PLoS One. 2012;7: e47391.
15. Stanford University. HIV Drug Resistance Database: Stanford University. Available at: http://hivdb.stanford.edu. Accessed on February 2, 2015.
16. Bastard M, Pinoges L, Balkan S, et al. Timeliness of clinic attendance is a good predictor of virological response and resistance to antiretroviral drugs in HIV-infected patients. PLoS One. 2012;7:e49091.
17. Pujades-Rodriguez M, Balkan S, Arnould L, et al. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304:303-312.
18. Cole TJ, Flegal KM, Nicholls D, et al. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ. 2007; 335:194.
19. World Health Organization (WHO). Global Strategy for the Surveillance and Monitoring of HIV Drug Resistance. 2012. http://www.who.int/hiv/ pub/drugresistance/drug-resistance-strategy/en/.
20. Aghokeng AF, Kouanfack C, Eymard-Duvernay S, et al. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon. J Int AIDS Soc. 2013;16:18004.
21. Barth RE, van der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10: 155-166.
22. Dagnra AY, Vidal N, Mensah A, et al. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc. 2011;14:30.
23. El-Khatib Z, DeLong AK, Katzenstein D, et al. Among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res. 2011;2:117.
24. El-Khatib Z, Ekstrom AM, Ledwaba J, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24:1679-1687.
25. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis. 2012;54:1660-1669.
26. Hosseinipour MC, Gupta RK, Van ZG, et al. Emergence of HIV drug resistance during first-and second-line antiretroviral therapy in resourcelimited settings. J Infect Dis. 2013;207(suppl 2):S49-S56.
27. Khienprasit N, Chaiwarith R, Sirisanthana T, et al. Incidence and risk factors of antiretroviral treatment failure in treatment-naive HIV-infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther. 2011;8:42.
28. Maldonado F, Biot M, Roman F, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg. 2009;103:607-612.
29. Messou E, Chaix ML, Gabillard D, et al. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Cote d'Ivoire, West Africa. J Acquir Immune Defic Syndr. 2013;64:211-219.
30. Wadonda-Kabondo N, Hedt BL, van Oosterhout JJ, et al. A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi. Clin Infect Dis. 2012;54 (suppl 4):S355-S361.
31. van Zyl GU, van der Merwe L, Claassen M, et al. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol. 2011;83:1764-1769.
32. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23:1867-1874.
33. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
34. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9:409-417.
35. Hamers RL, Sigaloff KC, Kityo C, et al. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Curr Opin HIV AIDS. 2013;8:19-26.
36. DeBeaudrap P, Thiam M, Diouf A, et al. Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal: results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr. 2013;62:381-387.
37. Ford N, Darder M, Spelman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: fiveyear follow up of an observational cohort. PLoS One. 2010;5:e10460.
38. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43:78-84.
39. Hanson DL, Adje-Toure C, Talla-Nzussouo N, et al. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses. 2009;25:489-495.
40. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drugresistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
41. Liao L, Xing H, Su B, et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. AIDS. 2013;27:1815-1824.
42. Hambisa MT, Ali A, Dessie Y. Determinants of mortality among HIV positives after initiating antiretroviral therapy in Western Ethiopia: a hospital-based retrospective cohort study. ISRN AIDS. 2013;2013:491601.
43. Kiwuwa-Muyingo S, Oja H, Walker AS, et al; Dart Trial Team. Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART. BMC Infect Dis. 2013;13:395.
44. Vinikoor MJ, Schuttner L, Moyo C, et al. Short communication: late refills during the first year of antiretroviral therapy predict mortality and program failure among HIV-infected adults in urban Zambia. AIDS Res Hum Retroviruses. 2014;30:74-77.
45. Poka-Mayap V, Pefura-Yone EW, Kengne AP, et al. Mortality and its determinants among patients infected with HIV-1 on antiretroviral therapy in a referral centre in Yaounde, Cameroon: a retrospective cohort study. BMJ Open. 2013;3.
46. Brinkhof MW, Boulle A, Weigel R, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med. 2009;6:e1000066.
47. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189.
48. Spillane H, Nicholas S, Tang Z, et al. Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users. Trop Med Int Health. 2012;17:1255-1263.
49. Estill J, Egger M, Johnson LF, et al. Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One. 2013;8:e57611.
50. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4:e5790.
51. Henriques J, Pujades-Rodriguez M, McGuire M, et al. Comparison of methods to correct survival estimates and survival regression analysis on a large HIV African cohort. PLoS One. 2012;7:e31706.